Moderate-Intensity Statin Selection and Dosing
For most patients requiring moderate-intensity statin therapy, initiate atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily, as these are the most commonly used and evidence-based options. 1
Specific Moderate-Intensity Statin Options
The 2018 ACC/AHA guideline defines moderate-intensity statins as those that lower LDL-C by approximately 30-49% 1:
- Atorvastatin 10-20 mg daily
- Rosuvastatin 5-10 mg daily
- Simvastatin 20-40 mg daily
- Pravastatin 40-80 mg daily
- Lovastatin 40 mg daily
- Fluvastatin 40-80 mg daily
- Pitavastatin 2-4 mg daily
Clinical Context for Moderate-Intensity Statin Initiation
Primary Prevention Populations
Initiate moderate-intensity statins without risk calculation in:
- Adults 40-75 years with diabetes and LDL-C ≥70 mg/dL 2
- Adults with 10-year ASCVD risk ≥7.5% after risk discussion 1, 2
- Borderline risk patients (5-7.5%) with risk-enhancing factors 1
Risk-enhancing factors that favor moderate-intensity statin therapy include:
- Family history of premature ASCVD
- Persistently elevated LDL-C ≥160 mg/dL
- Metabolic syndrome
- Chronic kidney disease
- History of preeclampsia or premature menopause
- Chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV)
- Persistent triglycerides ≥175 mg/dL
- High-sensitivity CRP ≥2.0 mg/L
- Lipoprotein(a) ≥50 mg/dL 2
Special Populations Where Moderate-Intensity May Be Preferred
Post-intracerebral hemorrhage patients: Recent 2025 real-world evidence demonstrates that moderate-intensity statins were associated with lower risks of recurrent ICH (HR 0.91), ischemic stroke (HR 0.68), composite vascular events (HR 0.74), and all-cause mortality (HR 0.87) compared to high-intensity statins, without increased adverse events 3. This represents a specific population where moderate-intensity is superior.
Elderly patients (≥75 years): Moderate-intensity statins used for ≥5 years in primary prevention showed decreased all-cause mortality (HR 0.80) without increased MACE risk after 5 years 4. This supports moderate-intensity as the preferred approach in this age group.
Practical Selection Algorithm
First-line choice: Atorvastatin 10-20 mg or rosuvastatin 5-10 mg
- Most evidence-based
- Widely available as generics
- Predictable LDL-C lowering
Alternative if statin intolerance concerns: Start with lower end of moderate-intensity range (atorvastatin 10 mg or rosuvastatin 5 mg)
If moderate-intensity insufficient: Add ezetimibe 10 mg rather than escalating to high-intensity statin 1. Emerging evidence suggests moderate-intensity statin plus ezetimibe may be superior to high-intensity statin monotherapy in terms of adherence and safety 5.
Monitoring and Follow-up
- Recheck lipid panel 4-12 weeks after initiation 2
- Target LDL-C reduction of ≥30% with moderate-intensity therapy 1
- Repeat every 3-12 months as needed 2
- Assess adherence and tolerability at each visit
Common Pitfalls to Avoid
Do not automatically escalate to high-intensity statins if moderate-intensity achieves adequate LDL-C reduction. The 2026 guideline expansion of statin eligibility includes many lower-risk individuals (mean 10-year ASCVD risk 3.1%) where moderate-intensity is appropriate 6.
Do not use high-intensity statins in post-ICH patients without compelling indication, given the superior outcomes with moderate-intensity therapy 3.
Do not overlook combination therapy: If LDL-C goals are not met on moderate-intensity statin, adding ezetimibe is reasonable before intensifying statin dose 1.